Novo Nordisk to pay $2 billion for new weight loss drug
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Step Aside, Novo Nordisk. This Is Europe’s No. 1 Company Now.
The two stocks have been trending in different directions for months. Here's what that says about the broader market.
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
STAT9h
Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug
Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.
Pharmaceutical Technology on MSN9h
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shot
Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...
FINAL REMINDER NVO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Novo Nordisk A/S Investors to Participate in the Class Action Lawsuit
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...
Becker's Hospital Review11h
Novo Nordisk expands access to reduced-cost Wegovy
Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug at retail ...